HLB INC. Logo

HLB INC.

A diversified group in pharma, shipbuilding, life sciences, and professional advisory services.

028300 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
세종특별자치시 연동면 명학산단서로 10-5, 세종특별자치시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Based on available information, HLB INC. appears to be a diversified global entity with activities spanning multiple sectors. Public sources indicate a primary focus on the pharmaceutical and biotechnology industries, with an emphasis on developing anti-cancer drugs through an open innovation system. The group also includes divisions engaged in shipbuilding and advanced composite materials, life sciences focusing on diagnostics and medical devices, and electrical engineering solutions. Additionally, the name HLB is associated with a global network of independent advisory and accounting firms offering audit, tax, and consulting services. The company's content suggests a focus on emerging business reporting standards, such as ESG and EU regulations, across various industries.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for HLB INC. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 5.0 KB
2025-09-18 00:00
Registration Form
증권신고서(합병)
Korean 5.0 MB
2025-09-17 00:00
M&A Activity
[첨부추가]주요사항보고서(회사합병결정)
Korean 42.9 KB
2025-09-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 129.4 KB
2025-09-08 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 11.2 KB
2025-09-03 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 41.0 KB
2025-09-01 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 138.5 KB
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-28 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-08-28 00:00
Environmental & Social Information
지속가능경영보고서등관련사항(자율공시)
Korean 11.1 KB
2025-08-20 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 43.1 KB

Automate Your Workflow. Get a real-time feed of all HLB INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HLB INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea 017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France NANO
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland NANOFH
NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland NNG
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany NN6
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain NAT
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea 168330
Naturland Holding PLC Logo
A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.
United Kingdom NATUR
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America 950220

Talk to a Data Expert

Have a question? We'll get back to you promptly.